Follow
Stefan Pöhlmann
Stefan Pöhlmann
Leiter der Abteilung Infektionsbiologie, Deutsches Primatenzentrum
Verified email at mail.de
Title
Cited by
Cited by
Year
SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
M Hoffmann, H Kleine-Weber, S Schroeder, N Krüger, T Herrler, ...
cell 181 (2), 271-280. e8, 2020
221732020
A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells
M Hoffmann, H Kleine-Weber, S Pöhlmann
Molecular cell 78 (4), 779-784. e5, 2020
19972020
Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
I Glowacka, S Bertram, MA Müller, P Allen, E Soilleux, S Pfefferle, I Steffen, ...
Journal of virology 85 (9), 4122-4134, 2011
12672011
SARS-CoV-2 variants B. 1.351 and P. 1 escape from neutralizing antibodies
M Hoffmann, P Arora, R Groß, A Seidel, BF Hörnich, AS Hahn, N Krüger, ...
Cell 184 (9), 2384-2393. e12, 2021
9932021
TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein
A Heurich, H Hofmann-Winkler, S Gierer, T Liepold, O Jahn, S Pöhlmann
Journal of virology 88 (2), 1293-1307, 2014
9922014
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry
H Hofmann, K Pyrc, L Van Der Hoek, M Geier, B Berkhout, S Pöhlmann
Proceedings of the National Academy of Sciences 102 (22), 7988-7993, 2005
9772005
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
M Hoffmann, N Krüger, S Schulz, A Cossmann, C Rocha, A Kempf, ...
Cell 185 (3), 447-456. e11, 2022
9172022
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
M Hoffmann, H Kleine-Weber, N Krüger, M Müller, C Drosten, ...
BioRxiv, 2020.01. 31.929042, 2020
9052020
Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies
D Wrapp, D De Vlieger, KS Corbett, GM Torres, N Wang, W Van Breedam, ...
Cell 181 (5), 1004-1015. e15, 2020
6702020
Diversity of receptors binding HIV on dendritic cell subsets
SG Turville, PU Cameron, A Handley, G Lin, S Pöhlmann, RW Doms, ...
Nature immunology 3 (10), 975-983, 2002
6672002
Protease inhibitors targeting coronavirus and filovirus entry
Y Zhou, P Vedantham, K Lu, J Agudelo, R Carrion Jr, JW Nunneley, ...
Antiviral research 116, 76-84, 2015
6562015
Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63
I Glowacka, S Bertram, P Herzog, S Pfefferle, I Steffen, MO Muench, ...
Journal of virology 84 (2), 1198-1205, 2010
5592010
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics
JD Reeves, SA Gallo, N Ahmad, JL Miamidian, PE Harvey, M Sharron, ...
Proceedings of the National Academy of Sciences 99 (25), 16249-16254, 2002
5382002
Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19
M Hoffmann, S Schroeder, H Kleine-Weber, MA Müller, C Drosten, ...
Antimicrobial agents and chemotherapy 64 (6), 10.1128/aac. 00754-20, 2020
5162020
Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research
G Simmons, P Zmora, S Gierer, A Heurich, S Pöhlmann
Antiviral research 100 (3), 605-614, 2013
5152013
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
M Hoffmann, K Mösbauer, H Hofmann-Winkler, A Kaul, H Kleine-Weber, ...
Nature 585 (7826), 588-590, 2020
4692020
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors
S Pfefferle, J Schöpf, M Kögl, CC Friedel, MA Müller, J Carbajo-Lozoya, ...
PLoS pathogens 7 (10), e1002331, 2011
4602011
Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts
S Bertram, A Heurich, H Lavender, S Gierer, S Danisch, P Perin, ...
PloS one 7 (4), e35876, 2012
4592012
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells
G Simmons, JD Reeves, CC Grogan, LH Vandenberghe, F Baribaud, ...
Virology 305 (1), 115-123, 2003
4532003
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans
S Pöhlmann, EJ Soilleux, F Baribaud, GJ Leslie, LS Morris, J Trowsdale, ...
Proceedings of the National Academy of Sciences 98 (5), 2670-2675, 2001
4532001
The system can't perform the operation now. Try again later.
Articles 1–20